novartis ceo on esg: pandemic has been a reset for pharma's reputation
Published 3 years ago • 2.6K plays • Length 4:11Download video MP4
Download video MP3
Similar videos
-
4:43
novartis ceo: our leukemia drug scemblix is a potential $3 billion plus medicine
-
7:41
novartis ceo on company's approach to covid-19 treatment
-
3:45
novartis not joining the 'frenzy' of weight loss drugs, ceo says
-
0:57
novartis global ceo vas narasimhan: ai's impact on pharma and clinical trial realities | n18s
-
24:07
novartis ceo vas narasimhan on the david rubenstein show
-
1:16:57
integrating esg into strategy | novartis lecture from nov 12, 2021
-
1:14:03
south asian trailblazers: vas narasimhan (ceo of novartis) and srishti gupta (leader in health & ed)
-
12:38
health care in a post-pandemic world with vas narasimhan novartis at cnbc evolve global summit 2021
-
7:51
watch cnbc's full interview with novartis ceo vas narasimhan
-
6:28
novartis ceo discusses developing a new covid-19 treatment
-
1:10
novartis commitment to esg
-
6:12
novartis ceo: expect continued growth in 2023
-
5:53
novartis expects 'strong momentum' going into second half, says ceo vasant narasimhan
-
0:44
ending the pandemic – how novartis supports the global vaccine supply
-
4:56
'we have reached an endemic environment with covid,' says novartis ceo
-
3:47
novartis ceo: demand has surged for therapeutics
-
4:22
novartis ceo on new cancer therapy programs
-
3:29
novartis generated $40 billion in innovative medicine sales, says ceo
-
4:54
novartis ceo: confident about continued sales growth for rest of year
-
3:42
novartis ceo vasant narasimhan on building trust with society
-
0:35
is esg a luxury or a necessity
-
2:12
novartis ceo: it will take over a year to find vaccine for coronavirus